{ "meta": { "data_length": 1, "message": "Statement id stmt:hc:tibsovo:1:1 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahc%3Atibsovo%3A1%3A1", "status": "success", "status_code": 200, "timestamp_elapsed": 0.002069, "timestamp_received": "2026-10-17T00:00:39.581486+00:00Z", "timestamp_returned": "2026-10-17T00:00:39.583555+00:00Z", "trace_id": "59874f5c-8359-4dee-8a0b-12d0f564f6bd" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hc:tibsovo:1:1", "type": "Statement", "description": "Health Canada approved ivosidenib as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hc:tibsovo", "type": "Document", "documentType": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product monograph]. HC.", "title": null, "aliases": [], "description": "Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.", "urls": [ "https://pdf.hres.ca/dpd_pm/00076398.PDF", "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103879" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hc", "type": "Agent", "agentType": "organization", "name": "Health Canada", "description": "Regulatory agency that approves drugs for sale and use in Canada." }, "description": "The organization that published this document." }, { "name": "company", "value": "Servier Canada Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tibsovo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ivosidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2024-07-19", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-07-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:191", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C4436", "conceptType": "Disease", "name": "Cholangiocarcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:CHOL", "code": "CHOL", "name": "Cholangiocarcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Cholangiocarcinoma+%28CHOL%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C4436", "code": "C4436", "name": "Cholangiocarcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C4436" ] } }, "objectTherapeutic": { "id": "tx:ncit:C114383", "conceptType": "Therapy", "name": "Ivosidenib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:2049873", "code": "2049873", "name": "ivosidenib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2049873" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:1560123", "code": "1560123", "name": "ivosidenib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/1560123" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "IDH1 inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C114383", "code": "C114383", "name": "Ivosidenib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:75", "present": true, "subject": { "id": "bmkr:75", "type": "CategoricalVariant", "name": "IDH1 p.R132G", "constraints": [ { "type": "DefiningAlleleConstraint", "allele": { "id": "ga4gh:VA.aAXNeFGBgeJUGbun-bKvgoW204tC1xdp", "type": "Allele", "name": "NP_005887.2:p.Arg132Gly", "aliases": [ "NP_005887.2:p.R132G", "IDH1 p.R132G" ], "description": "VRS variation of NP_005887.2:p.Arg132Gly", "digest": "aAXNeFGBgeJUGbun-bKvgoW204tC1xdp", "expressions": [ { "syntax": "hgvs.p", "value": "NP_005887.2:p.Arg132Gly", "extensions": [ { "name": "hgvs.p_short", "value": "p.R132G" } ] } ], "location": { "id": "ga4gh:SL.c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Amino acid position 132 of the Refseq protein NP_005887.2, which is the protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4).", "digest": "c1wumiCWSPL2vagoeYClRf5Z1SuyrIdx", "sequenceReference": { "id": "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "type": "SequenceReference", "name": "NP_005887.2", "aliases": [ "ensembl:ENSP00000260985.2", "ga4gh:SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "refseq:NP_005887.2" ], "description": "The protein product of the MANE Select coding transcript for IDH1 (refseq:NM_005896.4), corresponding to the Refseq protein accession NP_005887.2.", "moleculeType": "protein", "refgetAccession": "SQ.VZMxTY2iB2G_EuwlpVZ0AnX6R-am08GZ", "residueAlphabet": "aa" }, "start": 131, "end": 132, "sequence": "R" }, "state": { "type": "LiteralSequenceExpression", "sequence": "G" } }, "relations": [] }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:5382", "conceptType": "Gene", "name": "IDH1", "primaryCoding": { "id": "coding:hgnc:5382", "code": "HGNC:5382", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000138413", "code": "ENSG00000138413", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000138413" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:3417", "code": "3417", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/3417" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_005896.4", "code": "NM_005896.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "2" }, { "name": "start_position", "value": 209113113 }, { "name": "end_position", "value": 209113113 }, { "name": "reference_allele", "value": "G" }, { "name": "alternate_allele", "value": "C" }, { "name": "cdna_change", "value": "c.394C>G" }, { "name": "protein_change", "value": "p.R132G" }, { "name": "variant_annotation", "value": "Missense" }, { "name": "exon", "value": 4 }, { "name": "rsid", "value": "rs121913499" }, { "name": "hgvsg", "value": "2:g.209113113G>C" }, { "name": "hgvsc", "value": "ENST00000345146.2:c.394C>G" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hc:tibsovo:1", "type": "Indication", "description": "TIBSOVO (ivosidenib) monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy.", "contributions": [ { "id": "ctrb:vanallenlab:2024-10-30:0", "type": "Contribution", "description": "Initial access of FDA approvals", "date": "2024-10-30", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hc:tibsovo", "type": "Document", "documentType": "Regulatory approval", "name": "Tibsovo (ivosidenib) [product monograph]. HC.", "title": null, "aliases": [], "description": "Servier Canada Inc. Tibsovo (ivosidenib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00076398.PDF. Published July 2024. Accessed June 2025.", "urls": [ "https://pdf.hres.ca/dpd_pm/00076398.PDF", "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103879" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hc", "type": "Agent", "agentType": "organization", "name": "Health Canada", "description": "Regulatory agency that approves drugs for sale and use in Canada." }, "description": "The organization that published this document." }, { "name": "company", "value": "Servier Canada Inc.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Tibsovo", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "ivosidenib", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2024-07-19", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2024-07-19", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }